Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07089199 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tislelizumab Combined With Anlotinib and Nab-paclitaxel in II-III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study

Study acronym: TitAN
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 1 month later Jul 10, 2026 → Aug 10, 2027
See other at-risk trials from Qilu Hospital of Shandong University

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 27 words
    • Study title revised
  2. Primary completion pushed from Jul 10, 2026 to Aug 10, 2027v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study title revised
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a single-arm prospective clinical trial. The primary objective of the study is to explore the efficacy and safety of preoperative neoadjuvant therapy with Tislelizumab combined with Anlotinib and Nab-Paclitaxel in resectable stage II-III non-small cell lung cancer.Finally, it provides new evidence-based medical evidence for the perioperative treatment of non-small cell lung cancer.
Trial Details
NCT Number NCT07089199
Lead Sponsor Qilu Hospital of Shandong University
Conditions
(from sponsor)		 NSCLC, Tislelizumab, Anlotinib, Nab-paclitaxel
Enrollment 34 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov